Modality
ERT
MOA
GLP-1ag
Target
TYK2
Pathway
Incretin
MelanomaEndometrial CaPV
Development Pipeline
Preclinical
~Sep 2014
→ ~Dec 2015
Phase 1
~Mar 2016
→ ~Jun 2017
Phase 2
Sep 2017
→ Dec 2031
Phase 2Current
NCT05618510
2,890 pts·PV
2023-05→2031-02·Active
NCT04996274
1,387 pts·PV
2017-09→2031-12·Recruiting
4,277 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2031-02-214.9y awayPh3 Readout· PV
2031-12-045.7y awayPh3 Readout· PV
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P2/3
Recruit…
P2/3
Active
Catalysts
Ph3 Readout
2031-02-21 · 4.9y away
PV
Ph3 Readout
2031-12-04 · 5.7y away
PV
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05618510 | Phase 2/3 | PV | Active | 2890 | 6MWD |
| NCT04996274 | Phase 2/3 | PV | Recruiting | 1387 | NT-proBNP |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-8662 | Pfizer | NDA/BLA | CD19 | |
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| MRK-3732 | Merck & Co | Phase 1 | TYK2 | |
| NVO-7840 | Novo Nordisk | Phase 2/3 | B7-H3 | |
| MRN-7601 | Moderna | Phase 2 | IL-13 | |
| ARG-1250 | Argenx | Phase 2 | C5 | |
| ILM-5680 | Illumina | Phase 2 | BET | |
| COR-9566 | Corcept | Approved | TYK2 | |
| CRS-184 | CRISPR Therapeutics | Phase 1/2 | AHR | |
| SND-9531 | Syndax | Phase 3 | TYK2 |